Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866047 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00866047 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 58 participants.
The verdict
NCT00866047, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
Interventions
- DRUG brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-03 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866047
The ClinicalTrials.gov registry entry for NCT00866047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which brentuximab vedotin is the first listed.
NCT00866047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00866047 about?
NCT00866047 is a clinical study titled "A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma". This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
What is the current status of trial NCT00866047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2009-03. Estimated completion is 2016-06.
What interventions are being tested in trial NCT00866047?
The interventions under investigation include: brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT00866047?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.